

Company Focus

21 January 2008 | 12 pages

ICICI Bank (ICBK.BO)

Buy: 3Q Results; Rising P&L, Slumbering Balance Sheet

- Rise of 35%, 20% ahead of our expectations, with P&L bias ICICI's profits were ahead of expectations, if qualitatively a little mixed. Key takeaways: a) P&L pickup, on fairly broad-based gains; b) asset quality drift continues, and growth appears to be slipping away; c) business focus: subsidiaries to the fore, as its (questionable) international focus continues. Overall, the P&L shine was likely dulled a bit by the balance sheet and its direction.
- P&L shows signs of an up-tick While margins are up (remaining low, but getting better positioned for expansion), fee income growth has accelerated to over 33% (in spite of slackening growth), and cost pressures appear to be stabilizing. There is some evidence of ICBK's potential to raise profitability (a long-held expectation) through its franchise.
- Balance sheet: quality and direction raise questions Balance sheet issues are likely to take center stage as: a) domestic loan growth moderates further (retail 12% yoy), b) int'l ops remain a key focus, in spite of questionable economics, and challenging markets, and c) asset deterioration continues at a steady (expected) pace. In sum, there are more questions than answers.
- Momentum and focus on subsidiaries ICBK's financial services subsidiaries' sustained momentum, and ICICI Securities' IPO intentions are likely to remain a market focus.
- Raise TP to Rs1,510 This incorporates higher subsidiary valuations, slower asset growth and easier rate environment. Maintain Buy/Low Risk (1L).

Statistical Abstract

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2006A	25,397	28.13	5.2	44.3	5.0	14.6	0.7
2007A	31,097	34.46	22.5	36.1	4.6	13.4	0.8
2008E	43,396	39.12	13.5	31.8	2.9	12.1	0.8
2009E	58,356	52.60	34.5	23.7	2.6	11.7	0.9
2010E	78,380	70.65	34.3	17.6	2.4	14.3	1.0


Source: Powered by dataCentral

See Appendix A-1 for Analyst Certification and important disclosures.

Target price change ☑ Results ☑

1L
Rs1,245.45
Rs1,510.00
21.2%
0.8%
22.1%
Rs1,385,610M
US\$35,338M





Aditya Narain, CFA¹

+91-22-6631-9879 aditya.narain@citi.com

Manish Chowdhary, CFA¹ +91-22-6631-9853

manish.chowdhary@citi.com

Himani Shah, CFA¹ himani.shah@citi.com

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

¹Citigroup Global Markets India Private Limited

Fiscal year end 31-Mar	2006	2007	2008E	2009E	2010E
Valuation Ratios					
P/E adjusted (x)	44.3	36.1	31.8	23.7	17.6
P/E reported (x)	44.3	36.1	31.8	23.7	17.6
P/BV (x)	5.0	4.6	2.9	2.6	2.4
P/Adjusted BV diluted (x)	5.1	4.6	2.9	2.7	2.4
Dividend yield (%)	0.7	0.8	0.8	0.9	1.0
Per Share Data (Rs)					
EPS adjusted	28.13	34.46	39.12	52.60	70.65
EPS reported	28.13	34.46	39.12	52.60	70.65
BVPS	249.55	273.27	432.40	474.94	524.50
Tangible BVPS	249.55	273.27	432.40	474.94	524.50
Adjusted BVPS diluted	245.96	269.34	427.33	469.38	518.36
DPS	8.50	10.00	10.50	11.00	12.00
Profit & Loss (RsM)					
Net interest income	41,870	66,357	96,307	129,650	176,939
Fees and commissions	30,019	43,309	58,467	78,930	98,662
Other operating Income	20,347	26,321	28,040	34,218	38,233
Total operating income	92,237	135,986	182,814	242,797	313,834
Total operating expenses	-44,795	-66,907	-90,063	-116,826	-147,354
Oper. profit bef. provisions	47,442	69,080	92,751	125,971	166,480
Bad debt provisions	-8,173	-22,264	-24,646	-32,916	-42,502
Non-operating/exceptionals	-8,303	-10,338	-11,000	-12,000	-12,000
Pre-tax profit	30,966	36,479	57,105	81,056	111,978
Tax	-5,565	-5,378	-13,706	-22,696	-33,595
Extraord./Min. Int./Pref. Div.	-4	-4	-4	-3	-3
Attributable profit	25,397	31,097	43,396	58,356	78,380
Adjusted earnings	25,397	31,097	43,396	58,356	78,380
Growth Rates (%)	5.0	00 F	10.5		
EPS adjusted	5.2	22.5	13.5	34.5	34.3
Oper. profit bef. prov.	60.5	45.6	34.3	35.8	32.2
Balance Sheet (RsM)					
Total assets	2,513,890	3,446,580	4,525,911	5,905,976	7,666,205
Avg interest earning assets	1,953,003	2,799,421	3,789,066	5,019,223	6,595,843
Customer loans	1,496,945	2,017,661	2,862,441	3,785,593	5,003,982
Gross NPLs	22,226	41,260	79,581	109,745	138,970
Liab. & shar. funds	2,513,890	3,446,580	4,525,911	5,905,976	7,666,205
Total customer deposits	1,650,832	2,305,102	3,218,029	4,469,492	6,071,431
Reserve for loan losses Shareholders' equity	17,274 225,560	34,377 246,533	55,998 477,553	86,572	125,769 578,535
	223,300	240,333	477,333	524,198	J/0,JJJ
Profitability/Solvency Ratios (%)					
ROE adjusted	14.6	13.4	12.1	11.7	14.3
Net interest margin	2.14	2.37	2.54	2.58	2.68
Cost/income ratio	48.6	49.2	49.3	48.1	47.0
Cash cost/average assets	2.1	2.2	2.3	2.2	2.2
NPLs/customer loans	1.5	2.0	2.8	2.9	2.8
Reserve for loan losses/NPLs	77.7	83.3	70.4	78.9	90.5
Bad debt prov./avg. cust. loans	0.7 90.7	1.3 87.5	1.0	1.0 84.7	1.0 82.4
Loans/deposit ratio Tier 1 capital ratio	90.7 9.2	87.5 7.7	89.0 11.8	84.7 10.0	82.4 9.1
Total capital ratio	9.2 13.4	10.1	11.0	10.0	9.1 11.9
	13.4	10.1	10.0	13.0	11.5

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Figure 1. ICICI Bank – 3Q08 I	Financial Higl	hlights (Rs n	nillion, %)			
Rs Million	3Q08	3Q07	YoY %	2008	QoQ%	Citi Investment Research Comments
Interest Income	79,118	56,009	41.3	75,165	5.3	
Interest Expense	(59,521)	(41,159)	44.6	(57,305)	3.9	
Net Interest Income	19,597	14,850	32.0	17,860	9.7	Strong showing - ahead of expectations, and backed by a slight margin expansion
Fee-Based Income	17,850	13,450	32.7	14,858	20.1	Meaningful pick up over the quarter, in spite of a moderation in asset growth
Other Non-Interest Income	6,416	6,356	0.9	5,861	9.5	Remains a driver of business, even as it incorporates an additional MTM charge of Rs1.5b (2q/Rs1.2b) on CDO/CDS exposure
Non Interest Income	24,266	19,806	22.5	20,719	17.1	
Operating Income	43,863	34,656	26.6	38,579	13.7	
Operating Expenses	(21,276)	(17,133)	24.2	(19,708)	8.0	Stabilising - helped by moderating asset growth
Pre-Provision Profit	22,587	17,524	28.9	18,871	19.7	
Charges for Bad Debts	(7,603)	(6,672)	14.0	(6,445)	18.0	In line with expectations, though could have been raised given ongoing deterioration
Pre-Tax Profit	14,983	10,852	38.1	12,427	20.6	
Tax	(2,681)	(1,751)	53.1	(2,401)	11.7	
Net Profit	12,302	9,101	35.2	10,026	22.7	20% ahead of our expectations - driven by NII
EPS	11.1	10.2	8.6	9.0	22.7	
Customer Loans	2,155,170	1,727,631	24.7	2,071,210	4.1	Moderating and increasingly dependent on the international book
Customer Deposits	2,297,790	1,968,928	16.7	2,283,070	0.6	Growth moderates - and its quality improves with a rising CASA level
AIEA	3,151,190	2,627,710	19.9	3,085,937	2.1	
AIBL	3,130,285	2,404,488	30.2	3,014,807	3.8	
Total Assets	3,766,995	2,958,321	27.3	3,649,442	3.2	Growing with the market/market share gain days are over
Avg Assets	3,708,219	2,891,023	28.3	3,609,382	2.7	
Gross Non-Performing Loans (NPL) excluding W/off	65,460	37,170	76.1	59,315	10.4	Steady deterioration - 10% QoQ, inline with the previous quarter, and retail asset biased - a drift, rather than anything decisive
Loan Loss Reserves (LLR)	(33,182)	(18,600)	78.4	(29,606)	12.1	
Shareholders' Funds	465,140	244,450	90.3	447,520	3.9	
Book Value Per Share	418	273	52.9	402	3.9	
Key Ratios (%)	3Q08	3007	Bps ∆ YoY	2008	Bps ∆ QoQ	
ROAA (annualized)	1.31	1.23	8	1.10	21	
ROAE (annualized)	10.58	14.89	-431	8.96	162	Pressured by large capital, and subsidiary investments
Net Interest Margin (bps)	230	226	4	223	7	Uptick - modest, but a positive, and possibly a benefit of easing balance-sheet growth
Fee Inc/Operating Income	40.7	38.8	189	38.5	218	Impressive, and the key positive takeaway from the results
Other Non-Interest Inc/Op Inc	55.3	57.1	-183	53.7	162	
Op. Cost/ Operating Income	48.5	49.4	-93	51.1	-258	
Loan-to-Deposit Ratio (LDR)	93.8	87.7	605	90.7	307	
NPL/Loan Ratio	3.0	2.2	89	2.9	17	
LLR/NPL Ratio	51	50	65	50	78	
Source: Company reports, Citi I	nvestment Res	search				

Figure 2. NIM (bps)






Figure 3. ICBK – Growth in Fee Incomes, %



Source: Company reports





4

P&L leads, balance sheet lags


It was a mixed quarter. While ICBK surprised quantitatively (20% ahead of our expectations) and qualitatively on the P&L, the balance sheet does not reveal very definite trends, and raises more questions that it provides answers. The quarter also reinforces ICICI's strong positioning in the broader financial services space in India. Management's plans to highlight and list some subsidiaries suggest that these businesses are probably going to be in greater focus over the near to medium term. They should also provide a source of profit, capital and market valuation benchmarks for the company. We look at these issues in greater detail later in this note.

P&L: Directionally positive


The P&L is a positive, and clearly highlights the earnings expansion potential of the existing balance sheet and its existing business franchise. The underlying profits were 20% ahead of our expectations, and unlike in the past, they were driven by key operating parameters, rather than through one-off gains, or suppressed provisioning. In order of importance, the key positives were in the form of:

- Margins ICBK's margin expanded to about 230bps (vs. 223 the previous quarter), in a quarter where we expect the broader sector to continue to face pressure. While margins remain well under industry averages, we believe the margin support was likely generated by slowing balance sheet growth (which enabled ICBK to improve its deposit mix), and possibly some easing in the interest rate environment during the quarter. Importantly, the quarter did suggest that ICBK could start to return to industry level margins a long held expectation, although there are recent indications of this. Additionally, we believe the easier interest rate environment (which would support a meaningfully whole-sale borrower like ICBK), the new reality of easier asset growth, and a meaningful expansion in ICBK's branch base over the near term, should also contribute to an uptrend.
- Fee income The bank's fee income bounced to 32%+ yoy growth (20% qoq), after a decline to 25% in the previous quarter. While the previous quarter did have some one-offs, we believe the current quarter is impressive because: 1) growth has exceeded balance-sheet expansion and ICBK has tended to depend meaningfully on asset-linked fees; 2) the international markets have been soft, and 3) it is fairly broad-based across segments. We do see this as a fairly impressive aspect of the quarter, and we believe it augurs well for the quality of earnings.

Figure 5.ICBK – Gross and Net NPLs (%)




Source: Company reports and Citi Investment Research



Source: Company reports and Citi Investment Research





Source: Company reports and Citi Investment Research

Operating expenses growth moderates — ICBK's operating expense growth has also moderated a little to about 24%, which is lower than in many of the past quarters. While this was helped by relatively modest balance-sheet expansion, we do note some stability in its cost expansion, also reflected in a marginally lower cost-to-income ratio. While this may not necessarily continue in the immediate term – there is aggressive branch expansion under way and some of these costs will show up – we sense costs are stabilizing. If ICBK is able to continue to show upsides on margins and fees it would provide a potential driver of operating leverage.

Balance sheet: More questions than answers

ICBK's balance-sheet performance is a little soft, and while not meaningfully directional, it does raise three key points:


1) Asset quality: Weak, but along expected lines — ICBK recorded an estimated 10% qoq deterioration in its loan book. This was consistent with the previous quarter, with deterioration predominantly in the unsecured retail space. This just sustains the trend and suggests that asset quality remains a watch and pressure point. This is not alarming, however, or meaningfully damaging to earnings or the book. Its toll on the P&L, in the form of provisions, was in line with historical levels, with no change in provisioning levels/coverage. While we expect asset quality to remain an overhang, for this quarter and in the near future it does appear to constitute a source of incremental pain or pleasure.

2) Loan growth: Moderating, and how much lower will it go — In the domestic market, ICBK probably lost market share in the last quarter, a role fairly dramatically reversed over the last year or so. This was in large measure because of its significant retail bias at 61% of its loans, and growing at about 12% yoy, a pace that appears lower than the broader industry. In addition, negative growth in its rural/agricultural portfolio continued on a yoy basis. This was in part because of a seasonal impact, and as ICBK has sought to streamline lending practices, given some operational losses last year. Effectively, the 25% loan growth that it managed in the quarter was driven by its international loan book, which carries a host of other issues, which we discuss later in the note.

The key question is how much will growth moderate, and will it remain the growth bank/stock it has long been viewed as. Our sense is that ICBK's relatively skewed exposure to the retail and international segments, does raise its growth risks. In the near term, ICBK could well be a lower-than-industry growth bank. We believe it could try and avert this growth moderation by aggressively lending to the corporate sector, but this would necessitate another strategic shift in a short time, which could carry some execution risk. We would expect increased lending to this segment to balance the loan book, but it would have to be a dramatic shift to this segment if ICBK is to get back to above-industry growth.

Is lower growth necessarily negative? We do not think so; if anything, we believe a period of consolidation, and portfolio balancing on the asset and the deposit side, would be good, and is probably necessary (P&L and balance-sheet perspective), but it could impact the growth stock positioning that ICBK has held.

Figure 8. ICBK – International Business Loan Growth (Rs bn , %)



Source: Company Reports and Citi Investment Research 3) International loan book: The leading growth question — ICBK's offshore loan book, primarily to Indian corporates, continues as its growth driver. In the current quarter, this growth was over 100% yoy (though more moderate than the previous quarter), accounting for the bulk of ICBK's 25% loan growth. Equally importantly, its international loans now account for about 23% of its loan book (21% in 2Q08). Management also suggests that it will seek to grow this portfolio at about the same absolute level in the current calendar year, if market conditions are ok.

For us, the value/economics and the necessity of such a large international loan book has become even more questionable. And from a balance and return perspective, at 23% of loans it is well in excess of the 10-15% that we believe would probably be appropriate. Critically, in our view, this lending part of its business probably carries a diminishing return to scale (given that it would remain predominantly driven by wholesale funding) – in sharp contrast to the domestic business, where the franchise should feed off itself, and generate an increasing return on scale.

We believe this continued focus on the international books also sticks out sorely in the context of the current global credit markets, where borrowing spreads are such that incremental growth, if at all possible, will probably be fairly low profit and potentially higher on the risk spectrum. Management's large portfolio and its suggestion that it will continue to pursue this strategy – keeping markets in mind – is likely to increasingly influence valuations, and in our view, this influence will be more negative than positive.

Financial services subsidiaries: To the fore

Analysts (us included), the market, and clearly the bank's management are increasingly shifting focus to ICBK's financial services subsidiaries. These units have for some time been an integral part of the markets 'sums of parts' valuations. The focus has also increased as India's financial services space (ex-banks), and its participants have increasingly sought equity listings.

ICBK's businesses have also done fairly well in the current year (highlighted in figure 9) – while the Life and General insurance businesses continue to be leaders, its other initiatives over the current year include: a) ICICI Securities: It has restructured the firm, and now is setting in place an aggressive distribution and retail broking effort (its on-line platform is already a market leader), and b) a venture capital business with US\$2.4bn of AUM and with a strong and long track record, it is seeking to aggressively expand its assets under management for alternative asset classes, and c) AMC is a top three player in the market, and is also seeking to push up its growth and expansion efforts.

ICBK has now announced that it will be listing ICICI Securities, and this could include an additional stake sale. It is also fairly likely to seek listing and/or sell down its stakes in some of it other businesses over the near to medium term. Such moves would create calibrated valuation benchmarks for these businesses, although as we mentioned earlier, the market is already factoring in what we believe are reasonable benchmarks for most of these businesses. While these measures would probably shift the spotlight from the basic lending business, they should also be a source of capital returns for ICBK (needed, given its low return levels), and capital, which should provide it with even more flexibility in how it manages, grows, and restructures it businesses.

Figure 9. ICICI Bank Subsidiary Profit (Rs Million, %)

ICICI Bank Subsidiary	9M08	9M07	Yoy Growth (%)
ICICI Bank Consolidated	27620	22030	25%
ICICI Prudential Life Insurance			
Profit Impact	-6740	-2590	160%
APE	38800	23234	67%
NBAP	7480	5400	39%
ICICI Lombard General Insurance			
Premium	27220	23265	17%
PAT	1150	490	135%
ICICI Securities			
Revenues	5270	NA	NA
PAT	1080	NA	NA
Pru - ICICI AMC			
AUM	692300	333500	108%
PAT	750	330	127%
ICICI - Venture			
AUM	96000	NA	NA
PAT	520	NA	NA

Source: Company reports and Citi Investment Research

ICICI Bank

Company description

ICICI Bank was founded in 1994 by ICICI Ltd., which was then the country's leading development finance institution. It is a leader in retail lending, with more than 30% market share in all consumer-finance segments. ICICI Bank has international banking operations as its key focus area.

Investment strategy

Our Buy / Low Risk (1L) rating is premised on: (1) ICBK's broad exposure to the strong momentum in the Indian economy, and its strong market position in the Indian market; (2) a broad asset mix, which should reduce the risk and profitability strain from concentration; (3) the growing value of its subsidiary businesses; (4). the bank, in our view, offers one of the best exposures to the consumer finance and financial services opportunity in India, and has been at the forefront of building market leadership in most products, and (5) its strong and deep management team. ICICI Bank also offers large exposure to the corporate lending and capex cycle, which should be viewed against the economy's bright prospects.

Valuation

We raise our target price to Rs1,510 (from Rs1,235), based on our EVA model, which captures the long-term value of the business and is a standard valuation measure for our India banking universe.

Our target price revision is on account of: a) higher value for subsidiaries – now valued at Rs386 (previous Rs313), b) lower risk-free rate – we now factor in 7.75% (8%), given the recent fall in interest rates, and the outlook, and c) lower asset growth expectations over the longer term. Our target price is premised on the following: (1) a risk-free rate of 7.75%; (2) a long-term loan loss of 100bps; and (3) subsidiary value of Rs386 per share (Rs313 earlier).

We also use a sum-of-parts methodology, benchmarking valuations to individual businesses. By this measure, our fair value for ICICI Bank is Rs1,383 (up from Rs1,200 previously). We value ICICI Bank's banking business on a 2.25x FY09E PBV (2XFY09E PBV earlier), reflecting the leverage potential of the business as also peer company valuations, but also factoring in its ROE, which is currently below its cost of capital. In addition, we factor in Rs386 as the value of its subsidiaries (Previously Rs313) – specifically, these are; Life insurance business at Rs246 per share (18X FY09E NBAP), general insurance at Rs40per share (20X FY09E PE), AMC at Rs27 per share (8% of AUM), ICICI Securities at Rs55 per share (20X FY09E), venture fund at Rs21per share (15% of FY09E AUM).

We prefer to use EVA as our primary methodology because we believe it better adjusts for the relatively dynamic cost of capital and better captures the longterm value of the business.

Risks


Our risk rating is Low based on our quantitative risk-rating system, which tracks 260-day historical share price volatility. The downside risks that could impede the shares from reaching our target price include: (1) continued deterioration in asset quality; (2) low margins, with a limited cushion if there is further downside pressure; (3) aggressive growth in a range of business areas raises the risk of some failures; (4) aggressive international operations where returns appear low, and risk levels relatively high, and (5) inability to leverage capital, which keeps ROEs low.

Appendix A-1

Analyst Certification

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of all or any identified portion of this research report hereby certifies that, with respect to each issuer or security or any identified portion of the report with respect to an issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed by that research analyst, strategist or research associate in this research report report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s), strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

IMPORTANT DISCLOSURES



Customers of the Firm in the United States can receive independent third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at http://www.smithbarney.com (for retail clients) or http://www.citigroupgeo.com (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of ICICI Bank.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from ICICI Bank

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from ICICI Bank.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from ICICI Bank in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): ICICI Bank.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: ICICI Bank.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: ICICI Bank.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

The Firm is a market maker in the publicly traded equity securities of ICICI Bank.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution							
Data current as of 31 December 2007	Buy	Hold	Sell				
Citi Investment Research Global Fundamental Coverage (3421)	50%	37%	12%				
% of companies in each rating category that are investment banking clients	52%	53%	40%				

Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk rating. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underperf

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 18 January 2008 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to ICICI Bank. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product is for information on such secur

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi

Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

© 2008 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc and its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use,

Citigroup Global Markets | Equity Research

duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm has no reviewed the linked site. Equally, except to the addresses or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST